日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Exploring the activity of a novel orally bioavailable β-lactam-β-lactamase inhibitor combination, ceftibuten-ledaborbactam, against Enterobacterales-carrying bla(OXA-48)

探索一种新型口服生物利用度高的β-内酰胺-β-内酰胺酶抑制剂组合头孢布烯-雷达博巴坦对携带bla(OXA-48)基因的肠杆菌科细菌的活性

期刊:Microbiology Spectrum
影响因子:3.8
doi:10.1128/spectrum.03148-25
Mojica, Maria F; Zeiser, Elise T; Becka, Scott A; Six, David A; Moeck, Greg; Bonomo, Robert A; Papp-Wallace, Krisztina M
微生物学
发表日期：2026
文献求助 收藏

Spectrum of cefepime-taniborbactam coverage against 190 β-lactamases defined in engineered isogenic Escherichia coli strains

头孢吡肟-他尼博巴坦对工程化同源大肠杆菌菌株中定义的190种β-内酰胺酶的抗菌谱

期刊:Antimicrobial Agents and Chemotherapy
影响因子:4.5
doi:10.1128/aac.01699-24
Uehara, Tsuyoshi; Chatwin, Cassandra L; Miller, Brittany; Edwards, Mitchell; Stevenson, Annie; Colombo, Jenna; Six, David A; Daigle, Denis M; Moeck, Greg; Boyd, Steven A; Pevear, Daniel C
发表日期：2025
文献求助 收藏

Structure and mechanism of taniborbactam inhibition of the cefepime-hydrolyzing, partial R2-loop deletion Pseudomonas-derived cephalosporinase variant PDC-88

坦尼博巴坦抑制头孢吡肟水解酶、部分R2环缺失的假单胞菌来源头孢菌素酶变体PDC-88的结构和机制

期刊:Antimicrobial Agents and Chemotherapy
影响因子:4.5
doi:10.1128/aac.00078-25
Mack, Andrew R; Kumar, Vijay; Bethel, Christopher R; Taracila, Magdalena A; Miller, Brittany A; Uehara, Tsuyoshi; Six, David A; Papp-Wallace, Krisztina M; van den Akker, Focco; Bonomo, Robert A
发表日期：2025
文献求助 收藏

Burkholderia pseudomallei PenI β-lactamase and variants are potently inhibited by taniborbactam

类鼻疽伯克霍尔德菌 PenI β-内酰胺酶及其变体可被 taniborbactam 有效抑制

期刊:Antimicrobial Agents and Chemotherapy
影响因子:4.5
doi:10.1128/aac.00787-25
Mojica, Maria F; Becka, Scott A; Edwards, Mitchell; Myers, Cullen; Uehara, Kyoko; Uehara, Tsuyoshi; Hoshino, Tyuji; Zeiser, Elise T; Chatwin, Cassandra L; Six, David A; Bonomo, Robert A; Papp-Wallace, Krisztina M; Nukaga, Michiyoshi
发表日期：2025
文献求助 收藏

ARGONAUT-III and -V: susceptibility of carbapenem-resistant Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepime

ARGONAUT-III 和 -V：碳青霉烯类耐药肺炎克雷伯菌和多重耐药铜绿假单胞菌对双环硼酸β-内酰胺酶抑制剂他尼博巴坦联合头孢吡肟的敏感性

期刊:Antimicrobial Agents and Chemotherapy
影响因子:4.5
doi:10.1128/aac.00751-24
Jacobs, Michael R; Abdelhamed, Ayman M; Good, Caryn E; Mack, Andrew R; Bethel, Christopher R; Marshall, Steven; Hujer, Andrea M; Hujer, Kristine M; Patel, Robin; van Duin, David; Fowler, Vance G; Rhoads, Daniel D; Six, David A; Moeck, Greg; Uehara, Tsuyoshi; Papp-Wallace, Krisztina M; Bonomo, Robert A
肺炎
发表日期：2024
文献求助 收藏

ARGONAUT-IV: susceptibility of carbapenemase-producing Klebsiella pneumoniae to the oral bicyclic boronate β-lactamase inhibitor ledaborbactam combined with ceftibuten

ARGONAUT-IV：产碳青霉烯酶肺炎克雷伯菌对口服双环硼酸β-内酰胺酶抑制剂ledaborbactam联合头孢布烯的敏感性

期刊:Antimicrobial Agents and Chemotherapy
影响因子:4.5
doi:10.1128/aac.01127-24
Jacobs, Michael R; Good, Caryn E; Abdelhamed, Ayman M; Mack, Andrew R; Bethel, Christopher R; Marshall, Steven H; Hujer, Andrea M; Hujer, Kristine M; Patel, Robin; van Duin, David; Fowler, Vance G; Rhoads, Daniel D; Six, David A; Moeck, Greg; Uehara, Tsuyoshi; Papp-Wallace, Krisztina M; Bonomo, Robert A
肺炎
发表日期：2024
文献求助 收藏

Cefepime-taniborbactam demonstrates potent in vitro activity vs Enterobacterales with bla(OXA-48)

头孢吡肟-他尼博巴坦对具有 bla(OXA-48) 基因的肠杆菌科细菌表现出强效的体外活性

期刊:Microbiology Spectrum
影响因子:3.8
doi:10.1128/spectrum.01144-24
Mojica, Maria F; Zeiser, Elise T; Becka, Scott A; Six, David A; Moeck, Greg; Papp-Wallace, Krisztina M
微生物学
发表日期：2024
文献求助 收藏

Cefepime-taniborbactam activity against antimicrobial-resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa: GEARS global surveillance programme 2018-22

头孢吡肟-他尼博巴坦对耐药肠杆菌科和铜绿假单胞菌临床分离株的活性：GEARS全球监测计划2018-2022

期刊:Journal of Antimicrobial Chemotherapy
影响因子:3.6
doi:10.1093/jac/dkae329
Karlowsky, James A; Wise, Mark G; Hackel, Meredith A; Six, David A; Uehara, Tsuyoshi; Daigle, Denis M; Pevear, Daniel C; Moeck, Greg; Sahm, Daniel F
发表日期：2024
文献求助 收藏

In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program

2018年至2020年头孢吡肟-他尼博巴坦及其对照药物对革兰氏阴性杆菌临床分离株的体外活性：全球抗菌药物耐药性监测评估（GEARS）计划的结果

期刊:Antimicrobial Agents and Chemotherapy
影响因子:4.5
doi:10.1128/aac.01281-22
Karlowsky, James A; Hackel, Meredith A; Wise, Mark G; Six, David A; Uehara, Tsuyoshi; Daigle, Denis M; Cusick, Susan M; Pevear, Daniel C; Moeck, Greg; Sahm, Daniel F
发表日期：2023
文献求助 收藏

Examining the activity of cefepime-taniborbactam against Burkholderia cepacia complex and Burkholderia gladioli isolated from cystic fibrosis patients in the United States

研究头孢吡肟-他尼博巴坦对从美国囊性纤维化患者中分离出的洋葱伯克霍尔德菌复合群和唐菖蒲伯克霍尔德菌的活性

期刊:Antimicrobial Agents and Chemotherapy
影响因子:4.5
doi:10.1128/aac.00498-23
Mojica, Maria F; Zeiser, Elise T; Becka, Scott A; LiPuma, John J; Six, David A; Moeck, Greg; Papp-Wallace, Krisztina M
发表日期：2023
文献求助 收藏